OBJECTIVE: To assess whether circulating insulin-like growth factor-1 (IGF-1), IGF-2, insulin-like growth factor-binding protein-1 (IGFBP-1), or IGFBP-3 were associated with endometrial cancer in postmenopausal women. STUDY DESIGN: Between 1987 and 1990, we conducted a case-control study of 405 women with endometrial cancer and 297 matched population-based controls. This analysis included 174 postmenopausal cases and 136 controls. RESULTS: In logistic regression models adjusted for potential confounders, higher IGF-1 levels were not positively associated with endometrial cancer: odds ratio (OR) for the highest tertile versus the lowest tertile = 0.63, 95% confidence interval (CI) = 0.30-1.32. Endometrial cancer was inversely associated with IGF-2 (OR for the highest tertile = 0.35, 95% CI = 0.18-0.69) and IGFBP-3 (OR for the highest tertile = 0.40, 95% CI = 0.21-0.77), and not associated with IGFBP-1. CONCLUSION: Serum IGF-1, IGF-2, and IGFBP-3, but not IGFBP-1, were inversely associated with endometrial cancer in postmenopausal women. These associations and the potential role of the IGF system in endometrial proliferation and carcinogenesis warrant further research.
OBJECTIVE: To assess whether circulating insulin-like growth factor-1 (IGF-1), IGF-2, insulin-like growth factor-binding protein-1 (IGFBP-1), or IGFBP-3 were associated with endometrial cancer in postmenopausal women. STUDY DESIGN: Between 1987 and 1990, we conducted a case-control study of 405 women with endometrial cancer and 297 matched population-based controls. This analysis included 174 postmenopausal cases and 136 controls. RESULTS: In logistic regression models adjusted for potential confounders, higher IGF-1 levels were not positively associated with endometrial cancer: odds ratio (OR) for the highest tertile versus the lowest tertile = 0.63, 95% confidence interval (CI) = 0.30-1.32. Endometrial cancer was inversely associated with IGF-2 (OR for the highest tertile = 0.35, 95% CI = 0.18-0.69) and IGFBP-3 (OR for the highest tertile = 0.40, 95% CI = 0.21-0.77), and not associated with IGFBP-1. CONCLUSION: Serum IGF-1, IGF-2, and IGFBP-3, but not IGFBP-1, were inversely associated with endometrial cancer in postmenopausal women. These associations and the potential role of the IGF system in endometrial proliferation and carcinogenesis warrant further research.
Authors: Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-18 Impact factor: 4.254
Authors: Sungshim Lani Park; Veronica Wendy Setiawan; Peter A Kanetsky; Zuo-Feng Zhang; Lynne R Wilkens; Laurence N Kolonel; Loïc Le Marchand Journal: Cancer Causes Control Date: 2011-06-23 Impact factor: 2.506
Authors: Louise A Brinton; Lori C Sakoda; Kirsten Frederiksen; Mark E Sherman; Susanne K Kjaer; Barry I Graubard; Jorgen H Olsen; Lene Mellemkjaer Journal: Gynecol Oncol Date: 2007-09-07 Impact factor: 5.482
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Donna D Baird; Greg Travlos; Ralph Wilson; David B Dunson; Michael C Hill; Aimee A D'Aloisio; Stephanie J London; Joel M Schectman Journal: Epidemiology Date: 2009-07 Impact factor: 4.822